XBI icon

SPDR S&P Biotech ETF

641 hedge funds and large institutions have $11.4B invested in SPDR S&P Biotech ETF in 2021 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 254 increasing their positions, 170 reducing their positions, and 77 closing their positions.

Holders
641
Holders Change
-9
Holders Change %
-1.38%
% of All Funds
11.29%
Holding in Top 10
20
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+25%
% of All Funds
0.35%
New
75
Increased
254
Reduced
170
Closed
77
Calls
$1.35B
Puts
$2.93B
Net Calls
-$1.58B
Net Calls Change
+$1.88B
Name Market Value Shares Shares
Change
Shares
Change %
SCM
726
Soleus Capital Management
Connecticut
CM
727
Caption Management
Oklahoma
SVI
728
Strategic Vision Investment
Hong Kong
Alkeon Capital Management
729
Alkeon Capital Management
New York
OSAM
730
O'Shaughnessy Asset Management
Connecticut
PCM
731
Prelude Capital Management
New York
IC
732
Ikarian Capital
Texas
DCM
733
Driehaus Capital Management
Illinois
BMCM
734
Black Maple Capital Management
Wisconsin
HT
735
HAP Trading
New York
PHS
736
PFM Health Sciences
California
ACM
737
Aquilo Capital Management
California
KCM
738
Kingdon Capital Management
New York
Jennison Associates
739
Jennison Associates
New York
HNB
740
Huntington National Bank
Ohio
PA
741
Perceptive Advisors
New York
CA
742
CHI Advisors
New York
AI
743
Atom Investors
Texas
LC
744
Lavaca Capital
Texas
GPCM
745
Granite Point Capital Management
Massachusetts
Point72 Asset Management
746
Point72 Asset Management
Connecticut
PI
747
PEAK6 Investments
Illinois
ACM
748
Atika Capital Management
New York
CAM
749
Cormorant Asset Management
Massachusetts
SFM
750
Sphera Funds Management
Israel